EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New perspectives on VEGF signalling in Alzheimer's disease

Cherelle E G Emery, Seth Love iD, J Scott Miners iD

Brain Pathology · 2026-09 · 36 (5)

DOI: 10.1111/bpa.70100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Pathology, online erschienen am 12.04.2026. Verfasst von Cherelle E G Emery und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cerebrovascular & Dementia Research Group, Learning and Research Building, Bristol Medical School, Translational Health Sciences, University of Brist…. Hauptthemen laut MEDLINE: Alzheimer Disease, Signal Transduction, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) signalling mediates pleiotropic effects within the brain, encompassing angiogenesis, neuronal survival, and immune signalling. There is growing interest in the role of VEGF signalling in the pathophysiology of Alzheimer's disease (AD). The generation of single‐cell brain atlases and recent large multi‐omic studies, including analysis of CSF and bloods alongside post‐mortem brain tissue, have provided novel insights into the role of VEGF signalling in AD. Disruption of the VEGF‐A/VEGFR2 signalling pathway, due in part to elevated soluble VEGFR1 expression may contribute to pathogenic angiogenesis, BBB leakiness, and neuronal loss in AD. Induction of VEGF‐B/VEGFR1 signalling in microglia suggests that dysregulated VEGF‐mediated immune cell signalling is a further influence on AD pathogenesis. A reduction in expression of the ‘protective’ VEGFR3 and co‐receptors neuropilin 1 and 2 has also been recently linked to cognitive decline in AD. In large clinical studies, lower VEGF‐A levels in CSF and serum, raised soluble VEGFR1in CSF and elevated PlGF in CSF and serum, are predictive of more rapid cognitive decline and accelerated Alzheimer's disease neuropathological change (ADNC). This review discusses findings from recent multi‐omic studies of large clinical and neuropathological studies that prompt reconsideration of the nature of VEGF signalling in AD and shed light on some of the complexities and previous conflicts within the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseSignal TransductionVascular Endothelial Growth Factor AHumansAnimalsBrain

Stichwörter der Autor:innen

Alzheimer's diseasePlGFVEGFR1VEGFR2VEGF‐AVEGF‐B

Substanzen

Vascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Cerebrovascular & Dementia Research Group, Learning and Research Building, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, UK.

ORCID-Profile: Seth Love, J Scott Miners

Zitieren

APA

Emery, C. E. G., Love, S., & Miners, J. S. (2026). New perspectives on VEGF signalling in Alzheimer's disease. Brain Pathology, 36(5). https://doi.org/10.1111/bpa.70100

Vancouver

Emery CEG, Love S, Miners JS. New perspectives on VEGF signalling in Alzheimer's disease. Brain Pathology. 2026;36(5). doi:10.1111/bpa.70100

BibTeX
@article{Emery2026,
  author = {Emery, Cherelle E G and Love, Seth and Miners, J Scott},
  title = {New perspectives on VEGF signalling in Alzheimer's disease},
  journal = {Brain Pathology},
  year = {2026},
  volume = {36},
  number = {5},
  doi = {10.1111/bpa.70100}
}
Kostenlos starten →